JUPITER NEUROSCIENCES, INC. Research and Development Expense
JUPITER NEUROSCIENCES, INC. (JUNS) reported Research and Development Expense of $600.35 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- JUPITER NEUROSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $600.35K, a 20.95% decline year-over-year.
- JUPITER NEUROSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $411.05K, a 11.93% decline year-over-year.
- JUPITER NEUROSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $43.68K, a 78.27% decline year-over-year.
- JUPITER NEUROSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $816.70K, a 788.57% increase year-over-year.
- JUPITER NEUROSCIENCES, INC. research and development expense for fiscal 2025 was $2.09M, a 323.53% increase from fiscal 2024.
- JUPITER NEUROSCIENCES, INC. research and development expense for fiscal 2024 was $492.66K, a 48.40% decline from fiscal 2023.
- JUPITER NEUROSCIENCES, INC. research and development expense for fiscal 2023 was $954.79K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $600.35K 10-Q · filed 2026-08-14 | $1.01M 10-Q · filed 2026-08-14 | $1.06M derived: sum of 3 quarters · filed 2026-08-14 | $1.87M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $411.05K 10-Q · filed 2026-05-14 | $454.73K derived: sum of 2 quarters · filed 2026-05-14 | $1.27M derived: sum of 3 quarters · filed 2026-05-14 | $2.03M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $43.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $860.38K derived: sum of 2 quarters · filed 2026-04-01 | $1.62M derived: sum of 3 quarters · filed 2026-08-14 | $2.09M 10-K · filed 2026-04-01 |
| 2025-09-30 | $816.70K 10-Q · filed 2025-11-14 | $1.58M derived: sum of 2 quarters · filed 2026-08-14 | $2.04M 10-Q · filed 2025-11-14 | $2.24M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $759.45K 10-Q · filed 2026-08-14 | $1.23M 10-Q · filed 2026-08-14 | $1.43M derived: sum of 3 quarters · filed 2026-08-14 | $1.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $466.75K 10-Q · filed 2026-05-14 | $667.75K derived: sum of 2 quarters · filed 2026-05-14 | $759.66K derived: sum of 3 quarters · filed 2026-05-14 | $860.74K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $292.92K derived: sum of 2 quarters · filed 2026-04-01 | $393.99K derived: sum of 3 quarters · filed 2026-04-01 | $492.66K 10-K · filed 2026-04-01 |
| 2024-09-30 | $91.91K 10-Q · filed 2025-11-14 | $192.99K derived: sum of 2 quarters · filed 2025-11-14 | $291.65K 10-Q · filed 2025-11-14 | $536.38K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $101.08K 10-Q · filed 2025-08-19 | $199.74K 10-Q · filed 2025-08-19 | $444.47K derived: sum of 3 quarters · filed 2025-08-19 | $683.93K derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | $98.67K 10-Q · filed 2025-05-15 | $343.40K derived: sum of 2 quarters · filed 2025-05-15 | $582.86K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $244.73K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $484.19K derived: sum of 2 quarters · filed 2025-03-28 | $954.79K 10-K · filed 2025-03-28 | |
| 2023-09-30 | $239.46K 10-Q · filed 2024-12-23 | $710.06K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |